30 articles in this topic
What a senescent cell is, how a small population drives systemic inflammation, and an honest account of senolytic human data — early-phase, mechanistic, and short of any outcome a patient cares about.
A deep mechanistic dive into the signaling cascades, epigenetic reprogramming, and translational science behind parabiosis — from GDF11 controversies to clinical plasma trials.
Go beyond the basics of parabiosis to explore the specific proteins, exosomes, and signaling pathways that make young blood rejuvenating — and old blood damaging.
Discover how scientists joined the circulatory systems of young and old mice — and what it taught us about the surprising power of bloodstream factors to reverse signs of aging.
Master the cutting-edge molecular science of TGF-β-driven fibrosis — from epigenetic reprogramming and mechanotransduction to next-generation therapeutic strategies targeting specific pathway nodes in aging tissue.
Go beyond the basics and explore the precise molecular machinery that drives TGF-β-mediated fibrosis in aging — from receptor activation to Smad cascades, myofibroblast transformation, and emerging therapeutic targets.
Discover how your body's own repair system can backfire with age, turning helpful healing signals into a slow build-up of scar tissue that stiffens organs and drives aging.
Dive into the cutting-edge science of senescent cell targeting — from PROTAC-based degraders and tissue-specific delivery to trial data, biomarker strategies, and the future of combination therapies.
Go beyond the basics and explore the precise molecular mechanisms that make senolytic and senomorphic therapies tick — from BCL-2 inhibition to SASP signaling networks.
Discover how 'zombie cells' drive aging and how cutting-edge therapies are learning to clear them out — and what this means for a longer, healthier life.
A deep mechanistic exploration of how integrins sense and transmit physical forces at the atomic level, how aging corrupts these processes at every molecular step, and how emerging therapeutics target the mechanosensing axis to reverse age-related tissue dysfunction.
Go deeper into the molecular mechanics of how integrins activate FAK, Rho GTPases, and YAP/TAZ — and why these pathways derail as the extracellular matrix stiffens with age.
